Life Science Leader
Serina Therapeutics has billed its POZ (polyoxazoline) platform as the next generation of polymer-aided drug delivery, following logically from PEG (polyethylene glycol) and PEGylation, the drug delivery platform Serina’s founders first helped commercialize.
POZ is designed for a wide variety of applications and therapeutic areas and may offer substantial advantages in terms of drug safety and efficacy. Serina has three drug-POZ conjugates in preclinical development, with the lead candidate, POZ-rotigotine (SER-214), a weekly injection for Parkinson’s disease and restless leg syndrome, headed to the clinic in late 2013 or early 2014 ahead of the other two candidates, both in cancer.
To read the rest of the story in Life Science Leader, click here.